When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie. The company, Tolerance Bio, focuses on preserving the body’s ...
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
Extending human health span by several years is the vision of clock.bio, a biotech startup that is investigating the biology of cellular rejuvenation. The company recently raised $5.3 million in seed ...
Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...
SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback